Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy
Recruiting now · Not applicable
Conditions studied: Arrhythmogenic Right Ventricular Dysplasia
In brief
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.
Key facts
- Study ID
- NCT05209776
- Run by
- University Hospital, Toulouse
- People needed
- 80
- Starts
- 2022-02-01
- Expected to finish
- 2027-02-01
- Last updated by the study team
- 2026-06-01
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- For cases:
- Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria)
- Admitted for right ventricle electrophysiologic mapping
- For controls * Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts.
You may not qualify if…
- Diagnostic of systemic chronic inflammatory disease
- Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease.
- Taking immunosuppressant or immunomodulating medications
Where it is running
- Toulouse University Hospital Center — Toulouse, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.